| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Lanadelumab Basic information |
| Product Name: | Lanadelumab | | Synonyms: | Lanadelumab;Research Grade Lanadelumab (DHC04301);Research Grade Lanadelumab | | CAS: | 1426055-14-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lanadelumab Structure]() |
| | Lanadelumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lanadelumab Usage And Synthesis |
| Uses | Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema[1][2]. | | in vivo | Lanadelumab (20 mg/kg; i.v. or s.c.) shows a long half-life of about 12.5 days and blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys[2].
Lanadelumab (1, 30 mg/kg; s.c.) inhibits carrageenan-induced paw edema in the Male Sprague-Dawley rats [2]. | | References | [1] Riedl MA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020 Nov;75(11):2879-2887. DOI:10.1111/all.14416 [2] Kenniston JA, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014 Aug 22;289(34):23596-608. DOI:10.1074/jbc.M114.569061 |
| | Lanadelumab Preparation Products And Raw materials |
|